Factors associated with the discontinuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) after initiation of insulin

References

• International Diabetes Federation [Internet]. IDF Diabetes Atlas. 9th ed. Brussels, Belgium; 2019. Available from: http://www.diabetesatlas.org.
   Google Scholar
• Centers for Disease Control and Prevention [Internet]. National diabetes statistics report: estimates of diabetes and its burden in the United States; 2017 [cited 2019 May]. Available from: https://www.cdc.gov/diabetes/data/statistics/statistics-report.html.
   Google Scholar
• Patrick AR, Fischer MA, Choudhry NK, et al. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. J Gen Intern Med. 2014;29(2):320–327.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Dia Care. 2018;41(12):2669–2701.
   PubMed Web of Science ®Google Scholar
• Roussel R, Duran‐García S, Zhang Y, et al. Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: the CompoSIT‐I Study. Diabetes Obes Metab. 2018;21:781–790.
   Web of Science ®Google Scholar
• Linjawi S, Sothiratnam R, Sari R, et al. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin—The Sit2Mix trial. Primary Care Diabetes. 2015;9(5):370–376.
   PubMed Web of Science ®Google Scholar
• Optum, Inc. Optum® Clinformatics® for Market Intelligence, version 7.2 [Internet]. 2018 [cited 2019 Jul 7]. Eden Prairie, MN: Optum, Inc. Available from: https://www.optum.com/solutions/life-sciences/explore-data/advanced-analytics/market-intelligence.html.
   Google Scholar
• Xu Y, Pilla SJ, Alexander GC, et al. Use of non-insulin diabetes medicines after insulin initiation: a retrospective cohort study. PLoS One. 2019;14(2):e0211820.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Shankar RR, Lorber D, et al. A randomized clinical trial to evaluate the efficacy and safety of co-administration of sitagliptin with intensively titrated insulin glargine. Diabetes Ther. 2015;6(2):127–142.
   PubMed Web of Science ®Google Scholar
• Engel S, Wu F, Xu L, et al. Reduced incidence of hypoglycaemia with sitagliptin used with intensively titrated insulin may be due to factors other than the difference in insulin dose [Internet]. Stockholm (Sweden): EASD; 2015 [cited 2019 July 7]. Available from: https://www.easd.org/virtualmeeting/home.html#!resources/reduced-incidence-of-hypoglycaemia-with-sitagliptin-used-with-intensively-titrated-insulin-may-be-due-to-factors-other-than-the-difference-in-insulin-dose–2.
   Google Scholar
• Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006;55(2):517–522.
   PubMed Web of Science ®Google Scholar
• Ahren B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care. 2007;30(6):1344–1350.
   PubMed Web of Science ®Google Scholar
• Ahren B, Pacini G, Foley JE, et al. Improved meal-related -cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005;28(8):1936–1940.
   PubMed Web of Science ®Google Scholar
• Lyu X, Zhu X, Zhao B, et al. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Sci Rep. 2017;7(1):44865.
   PubMedGoogle Scholar
• Jensterle M, Goricar K, Janez A. Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. Endocr Res. 2017;42(4):261–268.
   PubMed Web of Science ®Google Scholar
• Pontiroli AE, Miele L, Morabito A. Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes, Obes Metabol. 2012;14(5):433–446.
   PubMed Web of Science ®Google Scholar
• Little S, Shaw J, Home P. Hypoglycemia rates with basal insulin analogs. Diabetes Technol Therap. 2011;13:S-53–S-64.
   Web of Science ®Google Scholar
• Rosenstock J, Fonseca V, Schinzel S, et al. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. J Diabetes Complications. 2014;28(5):742–749.
   PubMed Web of Science ®Google Scholar
• Owens DR, Traylor L, Mullins P, et al. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Res Clin Pract. 2017;124:57–65.
   PubMed Web of Science ®Google Scholar
• Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag. 2010;6:541–548.
   PubMedGoogle Scholar
• Dejager S, Schweizer A. Minimizing the risk of hypoglycemia with vildagliptin: clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Ther. 2011;2(2):51–66.
   PubMedGoogle Scholar
• Pohontsch NJ, Hansen H, Schäfer I, et al. General practitioners’ perception of being a doctor in urban vs. rural regions in Germany - A focus group study. Family Pract. 2018;35(2):209–215.
   PubMed Web of Science ®Google Scholar
• Hall JA, Irish JT, Roter DL, et al. Gender in medical encounters: an analysis of physician and patient communication in a primary care setting. Health Psychol. 1994;13(5):384–392.
   PubMed Web of Science ®Google Scholar
• Genere N, Sargis RM, Masi CM, et al. Physician perspectives on de-intensifying diabetes medications. Medicine. 2016;95(46):e5388.
   PubMed Web of Science ®Google Scholar